Urinary Bladder Neoplasms

"Urinary Bladder Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tumors or cancer of the URINARY BLADDER.

Descriptor ID	D001749
MeSH Number(s)	C04.588.945.947.960 C12.758.820.968 C12.777.829.813 C13.351.937.820.945 C13.351.968.829.707
Concept/Terms	Urinary Bladder Neoplasms Urinary Bladder Neoplasms Neoplasm, Urinary Bladder Urinary Bladder Neoplasm Neoplasms, Bladder Bladder Neoplasms Bladder Neoplasm Neoplasm, Bladder Bladder Tumors Bladder Tumor Tumor, Bladder Tumors, Bladder Urinary Bladder Cancer Urinary Bladder Cancer Cancer, Urinary Bladder Malignant Tumor of Urinary Bladder Cancer of the Bladder Bladder Cancer Bladder Cancers Cancer, Bladder Cancer of Bladder

Below are MeSH descriptors whose meaning is more general than "Urinary Bladder Neoplasms".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Urogenital Neoplasms [C04.588.945]
Urologic Neoplasms [C04.588.945.947]
Urinary Bladder Neoplasms [C04.588.945.947.960]
Male Urogenital Diseases [C12]
Urogenital Neoplasms [C12.758]
Urologic Neoplasms [C12.758.820]
Urinary Bladder Neoplasms [C12.758.820.968]
Urologic Diseases [C12.777]
Urinary Bladder Diseases [C12.777.829]
Urinary Bladder Neoplasms [C12.777.829.813]
Female Urogenital Diseases and Pregnancy Complications [C13]
Female Urogenital Diseases [C13.351]
Urogenital Neoplasms [C13.351.937]
Urologic Neoplasms [C13.351.937.820]
Urinary Bladder Neoplasms [C13.351.937.820.945]
Urologic Diseases [C13.351.968]
Urinary Bladder Diseases [C13.351.968.829]
Urinary Bladder Neoplasms [C13.351.968.829.707]

Below are MeSH descriptors whose meaning is related to "Urinary Bladder Neoplasms".

Below are MeSH descriptors whose meaning is more specific than "Urinary Bladder Neoplasms".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Urinary Bladder Neoplasms" by people in this website by year, and whether "Urinary Bladder Neoplasms" was a major or minor topic of these publications.

Bar chart showing 50 publications over 21 distinct years, with a maximum of 7 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	0	1	1
1995	2	0	2
2002	1	0	1
2004	1	0	1
2005	1	1	2
2007	1	0	1
2008	2	1	3
2009	3	0	3
2010	1	0	1
2011	2	0	2
2012	2	1	3
2013	2	0	2
2014	1	0	1
2015	7	0	7
2016	5	1	6
2017	2	0	2
2018	2	0	2
2019	3	0	3
2020	3	0	3
2021	2	0	2
2022	2	0	2

Below are the most recent publications written about "Urinary Bladder Neoplasms" by people in Profiles.

Rizzo A, Mollica V, Santoni M, Massari F. Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis. Clin Genitourin Cancer. 2022 10; 20(5):482-487.

View in: PubMed
Rizzo A, Mollica V, Santoni M, Ricci AD, Gadaleta-Caldarola G, Montironi R, Massari F. Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis. Future Oncol. 2022 Feb; 18(6):739-748.

View in: PubMed
Lannes F, Walz J, Maubon T, Rybikowski S, Fakhfakh S, Picini M, Tourret M, Brun C, Gravis G, Pignot G. Enhanced Recovery after Surgery for Radical Cystectomy Decreases Postoperative Complications at Different Times. Urol Int. 2022; 106(2):171-179.

View in: PubMed
Sun T, Hutchinson L, Tomaszewicz K, Caporelli ML, Meng X, McCauley K, Fischer AH, Cosar EF, Cornejo KM. Diagnostic value of a comprehensive, urothelial carcinoma-specific next-generation sequencing panel in urine cytology and bladder tumor specimens. Cancer Cytopathol. 2021 07; 129(7):537-547.

View in: PubMed
Mollica V, Maggio I, Lopez-Beltran A, Montironi R, Cimadamore A, Cheng L, Rizzo A, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Massari F. Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. Expert Rev Anticancer Ther. 2020 09; 20(9):755-763.

View in: PubMed
Cimadamore A, Aurilio G, Nol? F, Massari F, Scarpelli M, Santoni M, Lopez-Beltran A, Cheng L, Montironi R. Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. Cells. 2020 06 19; 9(6).

View in: PubMed
Regnier P, DE Luca V, Brunelle S, Sfumato P, Walz J, Rybikowski S, Maubon T, Branger N, Fakhfakh S, Durand M, Gravis G, Pignot G. Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy. Minerva Urol Nephrol. 2021 04; 73(2):215-224.

View in: PubMed
Lopez-Beltran A, Cheng L, Gevaert T, Blanca A, Cimadamore A, Santoni M, Massari F, Scarpelli M, Raspollini MR, Montironi R. Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers. Expert Rev Mol Diagn. 2020 02; 20(2):231-243.

View in: PubMed
Kouba E, Lopez-Beltran A, Montironi R, Massari F, Huang K, Santoni M, Chovanec M, Cheng M, Scarpelli M, Zhang J, Cimadamore A, Cheng L. Liquid biopsy in the clinical management of bladder cancer: current status and future developments. Expert Rev Mol Diagn. 2020 02; 20(2):255-264.

View in: PubMed
Cornejo KM, Cosar EF, Paner GP, Yang P, Tomaszewicz K, Meng X, Mehta V, Sirintrapun SJ, Barkan GA, Hutchinson L. Mutational Profile Using Next-Generation Sequencing May Aid in the Diagnosis and Treatment of Urachal Adenocarcinoma. Int J Surg Pathol. 2020 Feb; 28(1):51-59.

View in: PubMed

People

Explore

Similar Concepts

Top Journals